Noninvasive characterization of graft steatosis after liver transplantation

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 2, 2015, Pages 224-232

  Karlas, Thomas ^a   Kollmeier, Johanna ^a   Böhm, Stephan ^a   Müller, Jürgen ^a   Kovacs, Peter ^a   Tröltzsch, Michael ^a   Weimann, Antje ^a   Bartels, Michael ^a   Rosendahl, Jonas ^a   Mössner, Joachim ^a   Berg, Thomas ^a   Keim, Volker ^a   Wiegand, Johannes ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Controlled attenuation parameter; Elastography; Liver stiffness; NAFLD fibrosis score; Steatosis

Indexed keywords

DNA; INTERLEUKIN 28B; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PHOSPHOLIPASE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALCOHOL LIVER DISEASE; ALLELE; ARTICLE; ATTENUATION; BODY MASS; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ELASTOGRAPH; ELASTOGRAPHY; FATTY LIVER; FEMALE; GENETIC RISK; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT STEATOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONALCOHOLIC LIVER CIRRHOSIS; PARAMETERS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT ELASTOGRAPHY; TRANSPLANTATION; ULTRASOUND TRANSDUCER; ADVERSE EFFECTS; COHORT ANALYSIS; GENETICS; NON-ALCOHOLIC FATTY LIVER DISEASE; YOUNG ADULT;

ADULT; AGED; ALLELES; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; HUMANS; INTERLEUKINS; LIPASE; LIVER TRANSPLANTATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 84921412790     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.983156     Document Type: Article

References (41)

1. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013;27:195-208.
2. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, et al. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014;20:7089-103.
3. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007;13:844-7.
4. Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl 2012;18:1147-53.
5. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non-alcoholic fatty liver disease in liver transplant recipients. another story of "seed and soil". Am J Gastroenterol 2010;105:613-20.
6. Kim H, Lee K, Lee K, Yi N, Lee HW, Hong G, et al. Histologically proven nonalcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant 2014;28:521-9.
7. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-9.
8. Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl 2013;19:1377-86.
9. Vasuri F, Malvi D, Gruppioni E, Grigioni WF, D'Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol 2014;20:2810-24.
10. Alten TA, Negm AA, Voigtländer T, Jaeckel E, Lehner F, Brauner C, et al. Safety and performance of liver biopsies in liver transplant recipients. Clin Transplant 2014;28:585-9.
11. Barrault C, Roudot-Thoraval F, Tran Van Nhieu J, Atanasiu C, Kluger MD, Medkour F, et al. Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation. Clin Res Hepatol Gastroenterol 2013;37:347-52.
12. American Association for the Study of Liver Diseases (AASLD). AASLD endorses vibration controlled transient elastography. Press release, 20th March 2014.
13. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-18.
14. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled attenuation parameter (CAP). a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32: 902-10.
15. Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014;9:e91987.
16. Petta S, Grimaudo S, Cammà C, Cabibi D, Di Marco V, Licata G, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012;56:1356-62.
17. Finkenstedt A, Auer C, Glodny B, Posch U, Steitzer H, Lanzer G, et al. Patatin-like phospholipase domaincontaining protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013;11:1667-72.
18. Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012;12:737-44.
19. Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation. insight into mechanisms of disease. Am J Transplant 2013; 13:2450-7.
20. Castéra L, Foucher J, Bernard P, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement. a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-35.
21. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®). validation in chronic hepatitis C. J Viral Hepat 2012;19:244-53.
22. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score. a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
23. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012;55:1700-10.
24. Rosendahl J, Tönjes A, Schleinitz D, Kovacs P, Wiegand J, Ruffert C, et al. A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS One 2012;7:e29433.
25. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease. practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
26. Martín-Rodríguez JL, Arrebola JP, Jiménez-Moleón JJ, Olea N, González-Calvin JL. Sonographic quantification of a hepato-renal index for the assessment of hepatic steatosis in comparison with 3T proton magnetic resonance spectroscopy. Eur J Gastroenterol Hepatol 2014;26:88-94.
27. Crespo G, Fernández-Varo G, Mariño Z, Casals G, Miquel R, Martínez SM, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis. a prospective study. J Hepatol 2012;57:281-7.
28. Angulo P, BugianesiE, BjornssonES, CharatcharoenwitthayaP, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145:782-9.
29. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
30. El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant 2012;26:E505-12.
31. de Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014;60:1026-31.
32. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199-208.
33. Wong GL, Vergniol J, Lo P, Wai-Sun Wong V, Foucher J, Le Bail B, et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. Ann Hepatol 2013;12:570-80.
34. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis. a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:394-402.e1.
35. Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol 2014;60:910-12.
36. Macaluso FS, Maida M, Cammà C, Cabibbo G, Cabibi D, Alduino R, et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. J Hepatol 2014;61: 523-9.
37. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008;48:1718-23.
38. Mikolasevic I, Orlic L, Milic S, Lukenda V, Racki S, Stimac D, et al. Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. Wien Klin Wochenschr 2014;126:474-9.
39. Arslanow A, Stokes CS, Weber SN, Grünhage F, Lammert F, Krawczyk M. The common PNPLA3 variant is associated with hepatic steatosis quantified by controlled attenuation parameter and determines the fate of patients with chronic liver diseases [abstract]. J Hepatol 2014;60 (Suppl):S346.
40. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53:86-95.
41. Shen J, Wong GL, Chan HL, Chan H, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014;39:532-9.